Involvement of the mitochondrial pathway and Bim/Bcl-2 balance in dihydroartemisinin-induced apoptosis in human breast cancer in vitro

International Journal of Molecular Medicine

Volumn 31, Issue 1, 2013, Pages 213-218

  Mao, Haiting ^a   Gu, Hongtao ^a   Qu, Xun ^a   Sun, Jintang ^a   Song, Bingfeng ^a   Gao, Wenjuan ^a   Liu, Jia ^a   Shao, Qianqian ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Bcl 2; Bim; Breast cancer; Cell cycle; Dihydroartemisinin; Mitochondrial apoptosis; Proliferation

Indexed keywords

BIM PROTEIN; CASPASE 8; CASPASE 9; CYTOCHROME C; DIHYDROARTEMISININ; PROTEIN BCL 2;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DRUG CYTOTOXICITY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; SECRETORY PATHWAY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; ARTEMISININS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CASPASE 8; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOCHROMES C; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS;

EID: 84873125516     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1176     Document Type: Article

References (37)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Antoon JW, Lai R, Struckhoff AP, et al: Altered death receptor signaling promotes epithelial-to-mesenchymal transition and acquired chemoresistance. Sci Rep 2: 539, 2012.
3. White NJ: Qinghaosu (artemisinin): the price of success. Science 320: 330-334, 2008.
4. German PI and Aweeka FT: Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet 47: 91-102, 2008.
5. Efferth T: Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin - from bench to bedside. Planta Med 73: 299-309, 2007.
6. Efferth T, Dunstan H, Sauerbrey A, Miyachi H and Chitambar CR: The anti-malarial artesunate is also active against cancer. Int J Oncol 18: 767-773, 2001.
7. Klayman DL: Qinghaosu (artemisinin): an antimalarial drug from China. Science 228: 1049-1055, 1985.
8. Disbrow GL, Baege AC, Kierpiec KA, et al: Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res 65: 10854-10861, 2005.
9. Hosoya K, Murahari S, Laio A, London CA, Couto CG and Kisseberth WC: Biological activity of dihydroartemisinin in canine osteosarcoma cell lines. Am J Vet Res 69: 519-526, 2008.
10. Mercer AE, Copple IM, Maggs JL, O'Neill PM and Park BK: The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J Biol Chem 286: 987-996, 2011.
11. Zhang S and Gerhard GS: Heme mediates cytotoxicity from artemisinin and serves as a general anti-proliferation target. PLoS One 4: e7472, 2009.
12. Toovey S, Bustamante LY, Uhlemann AC, East JM and Krishna S: Effect of artemisinins and amino alcohol partner antimalarials on mammalian sarcoendoplasmic reticulum calcium adenosine triphosphatase activity. Basic Clin Pharmacol Toxicol 103: 209-213, 2008.
13. Handrick R, Ontikatze T, Bauer KD, et al: Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol Cancer Ther 9: 2497-2510, 2010.
14. Eckstein-Ludwig U, Webb RJ, Van Goethem ID, et al: Artemisinins target the SERCA of Plasmodium falciparum. Nature 424: 957-961, 2003.
15. Chen T, Li M, Zhang R and Wang H: Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cells to carboplatin therapy. J Cell Mol Med 13: 1358-1370, 2009.
16. Wang SJ, Gao Y, Chen H, et al: Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett 293: 99-108, 2010.
17. Chen M, Chen TS, Lu YY, Liu CY and Qu JL: Dihydroarteminsinin-induced apoptosis is not dependent on the translocation of Bim to the endoplasmic reticulum in human lung adenocarcinoma cells. Pathol Oncol Res 18: 809-816, 2012.
18. He Q, Shi J, Shen XL, et al: Dihydroartemisinin upregulates death receptor 5 expression and cooperates with TRAIL to induce apoptosis in human prostate cancer cells. Cancer Biol Ther 9: 819-824, 2010.
19. Singh NP and Lai H: Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 70: 49-56, 2001.
20. Singh NP and Lai HC: Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells. Anticancer Res 25: 4325-4331, 2005.
21. Zhang CZ, Zhang H, Yun J, Chen GG and Lai PB: Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol 83: 1278-1289, 2012.
22. Huang XJ, Ma ZQ, Zhang WP, Lu YB and Wei EQ: Dihydroartemisinin exerts cytotoxic effects and inhibits hypoxia inducible factor-1alpha activation in C6 glioma cells. J Pharm Pharmacol 59: 849-856, 2007.
23. Mercer AE, Maggs JL, Sun XM, et al: Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem 282: 9372-9382, 2007.
24. Gao N, Budhraja A, Cheng S, et al: Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo. Apoptosis 16: 511-523, 2011.
25. Reungpatthanaphong P and Mankhetkorn S: Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull 25: 1555-1561, 2002.
26. Yuan J, Murrell GA, Trickett A and Wang MX: Involvement of cytochrome c release and caspase-3 activation in the oxidative stress-induced apoptosis in human tendon fibroblasts. Biochim Biophys Acta 1641: 35-41, 2003.
27. Noori S and Hassan ZM: Dihydroartemisinin shift the immune response towards Th1, inhibit the tumor growth in vitro and in vivo. Cell Immunol 271: 67-72, 2011.
28. Aung W, Sogawa C, Furukawa T and Saga T: Anticancer effect of dihydroartemisinin (DHA) in a pancreatic tumor model evaluated by conventional methods and optical imaging. Anticancer Res 31: 1549-1558, 2011.
29. Kelman Z: PCNA: structure, functions and interactions. Oncogene 14: 629-640, 1997.
30. Lu JJ, Chen SM, Ding J and Meng LH: Characterization of dihydroartemisinin-resistant colon carcinoma HCT116/R cell line. Mol Cell Biochem 360: 329-337, 2012.
31. Morrissey C, Gallis B, Solazzi JW, et al: Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs 21: 423-432, 2010.
32. Renz A, Berdel WE, Kreuter M, Belka C, Schulze-Osthoff K and Los M: Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood 98: 1542-1548, 2001.
33. Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59, 2008.
34. Bouillet P, Purton JF, Godfrey DI, et al: BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 415: 922-926, 2002.
35. Zhao L, He F, Liu H, et al: Natural diterpenoid compound elevates expression of Bim protein, which interacts with antiapoptotic protein Bcl-2, converting it to proapoptotic Bax-like molecule. J Biol Chem 287: 1054-1065, 2012.
36. Wojciechowski S, Tripathi P, Bourdeau T, et al: Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. J Exp Med 204: 1665-1675, 2007.
37. Willis SN, Fletcher JI, Kaufmann T, et al: Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859, 2007.